Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.
Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166